PARIS--(BUSINESS WIRE)--Regulatory News:
ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today announced that it will host a Key Opinion Leader luncheon for investors focused on novel approaches to HIV therapy at 12:00pm Eastern Time on Monday, November 28, 2016 in New York.
The meeting will feature a keynote presentation by key opinion leader Professor Ian McGowan, MD, PhD, from the University Of Pittsburgh School Of Medicine, who will discuss current and novel approaches to the treatment of HIV.
ABIVAX's CEO, Professor Hartmut J. Ehrlich, MD, and Chief Medical Officer, Jean-Marc Steens, MD, will provide an overview of the Company’s ongoing clinical development work with ABX464, a novel, first-in-class small molecule inhibiting HIV replication through an entirely novel mechanism of action. Topline data from a second Phase IIa study in HIV patients in France, Belgium, and Spain are expected for the end of 2016/early 2017. Encouraging results of the first Phase IIa study in HIV-positive, treatment-naïve patients were reported early in 2016, indicating that ABX464 monotherapy was safe and well tolerated in this patient population, and that it demonstrated anti-viral activity.
Dr. Ian McGowan is a Professor of Medicine in the Division of Gastroenterology, Hepatology and Nutrition at the University Of Pittsburgh School Of Medicine. He qualified in medicine at the University of Liverpool, Liverpool, UK and has additional doctoral degrees from the University of Oxford (Mucosal Immunology) and the Liverpool School of Tropical Medicine (Microbicide Development). For the last decade, Dr. McGowan has been the Principal Investigator of the University of Pittsburgh-based Microbicide Trials Network (MTN), an HIV/AIDS clinical trials network established in 2006 by the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health (NIH). In addition, he has an active translational research program focused on the development of long-acting injectable antiretrovirals and rectal microbicides for HIV prevention. Dr. McGowan has also served as a consultant for the U.S. Centers for Disease Control and Prevention, the World Health Organization, and is a former Chair of the U.S. Food and Drug Administration Antiviral Drug Advisory Committee.
The event is intended for investors, analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a spot, please reply to this email or contact LifeSci Advisors, LLC at email@example.com.
About ABIVAX (www.abivax.com)
ABIVAX is an innovative biotechnology company focused on
targeting the immune system to eliminate viral disease. ABIVAX leverages
three technology platforms for drug discovery: an anti-viral, an immune
enhancement, and a polyclonal antibody platform. ABX464, its most
advanced compound, is currently in Phase II clinical trials and is a
first-in-class oral small anti-viral molecule which blocks HIV
replication through a unique mechanism of action. In addition, ABIVAX is
advancing multiple preclinical candidates against additional viral
targets (i.e. Chikungunya, Ebola, Dengue) as well as an immune enhancer,
and several of these compounds are planned to enter clinical development
within the next 18 months. A recently updated corporate presentation,
which includes a timeline for the company’s anticipated news flow, is
available at www.abivax.com.
Follow us on Twitter @ABIVAX_